Daewoong takes 30.2% stake in fellow Korean pharmaco HanAll
Daewoong Pharmaceutical Co. Ltd. acquired a 30.2% stake in HanAll Pharmaceutical Co. Ltd. Daewoong paid $94.1mm (KRW104.6bn) for 15.5mm HanAll shares (consisting of 6mm existing shares owned by HanAll chairman Kim Byung-tae and 9.5mm new shares through a rights offering), implying a $6.07 per-share price (an 8% discount).
- Drug Delivery
- Generic Drugs
- OTC, Consumer
- Includes Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.